Go Pro
NASDAQ:NXL

Nexalin Technology Q3 2025 Earnings Report

Nexalin Technology logo
$0.33 +0.00 (+0.45%)
As of 08/21/2026 04:00 PM Eastern

Nexalin Technology EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Nexalin Technology Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.04 million
Beat/Miss
Missed by -$21.85 thousand
YoY Revenue Growth
N/A

Nexalin Technology Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Friday, November 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Nexalin Technology's Q3 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedules

Earnings Documents

Nexalin Technology Earnings Headlines

Nexalin Technology Raises Liquidity via Short-Term Note
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL) is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions.

Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.

View Nexalin Technology Profile